$ENLV

Enlivex Ltd. (ENLV) plans to reduce its workforce by 60% and cut management salaries to focus on a Phase 2b trial for Allocetra, its treatment for knee osteoarthritis. The company aims to lower cash burn while awaiting topline data by mid-2027. Shares rose 5.02% in pre-market trading.

Enlivex Ltd. (Nasdaq: ENLV) said its management will host a July 30, 2026 investor webinar covering a recently announced private placement, its Rain protocol-based RAIN treasury strategy, and clinical progress for Allocetra. Enlivex also reported the FDA granted Allocetra RMAT designation for symptomatic knee osteoarthritis in patients aged 64+.

Enlivex Ltd. (ENLV) said the FDA granted RMAT designation to its Allocetra therapy for age-related symptomatic knee osteoarthritis in older adults. The RMAT decision cites results from its completed Phase I/IIa trial showing statistically significant improvements in pain and function vs placebo, durable to six months. Enlivex is starting a Phase IIb trial enrolling 182 patients and plans an FDA Type B meeting.

Investing.com reports the FDA granted RMAT designation to Enlivex’s experimental immunotherapy Allocetra for age-related knee osteoarthritis in patients 64+. The status may enable more frequent early FDA interactions and could support accelerated approval. Enlivex is running a Phase IIb trial to enroll 182 patients, with first U.S. dosing done and topline data expected by end of Q2 2027.

Enlivex Ltd. (Nasdaq: ENLV) announced a 1-for-15 reverse stock split effective July 9, 2026. Authorized shares fall from 2,375,000,000 to 158,333,334 and par value rises from NIS 0.40 to NIS 6.00. Issued shares drop from 252,480,222 to ~16,832,015, with proportional warrant/option adjustments. Shares continue trading under ENLV.

Enlivex Ltd. (Nasdaq: ENLV) said it will be a Gold Sponsor of Proof of Talk 2026 in Paris (June 2-3), hosting a curated dinner for institutional asset managers and allocators. CEO Dr. Oren Hershkovitz will present Enlivex’s “quality longevity” model combining clinical development with a prediction-markets treasury strategy built around the Rain Protocol on Arbitrum.

The article previews a short U.S. and Canada market week after Memorial Day, highlighting housing, confidence, jobs, and earnings. It lists U.S. EPS results for PDD, AutoZone, Elbit, Salesforce, Synopsys, Marvell, Costco, Dell, and Autodesk, plus Canada banks’ and other firms’ EPS. Key data include S&P Case-Shiller (March), jobless claims and durable goods (May 23/April), and Canada payroll employment and GDP.

Enlivex Ltd. (NASDAQ: ENLV) has received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has an initial 180-day period, until November 9, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to comply could lead to delisting, though Enlivex may be eligible for an additional 180-day period if other listing standards are met.

RedChip Companies will broadcast interviews with Enlivex Therapeutics (Nasdaq: ENLV) and Lantern Pharma (Nasdaq: LTRN) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, October 4th, at 7 p.m. ET. The interviews will cover Enlivex's positive Phase IIa results for Allocetra™ in knee osteoarthritis and Lantern Pharma's AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies will discuss their clinical pipelines and future development plans.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 500 points on Monday. The Dow traded up 0.65% to 46,546.82 while the NASDAQ rose 2.32% to 22,789.25. The S&P 500 also rose, gaining, 1.40% to 6,696.44. Communication services shares jumped by 3.1% on ...